Tibet Cheezheng Tibetan Medicine Co., Ltd is a China-based company, principally engaged in the research, development, manufacture and distribution of Tibetan medicines. The Company primarily offers medicines under emplastrum, ointment, granule, crude drugs and others. The Company's products include external pain relieving series, including Cheezheng Xiaotong emplastrum, Qingpeng ointment and Baimai ointment, as well as oral medicine series. The Company distributes its products within domestic market and to overseas markets.

Employees

3,170

Sector

Pharmaceuticals

Calendar

Apr. 23 - Q4 2025 Earnings Release

More about the company

Quotes

Date	Price	Change	Volume
26-01-14	24.51 ¥	-1.17%	5,017,459
26-01-13	24.80 ¥	+0.73%	5,924,561
26-01-12	24.62 ¥	+0.29%	3,582,099
26-01-09	24.55 ¥	+0.95%	3,339,142
26-01-08	24.32 ¥	+0.25%	2,050,123

End-of-day quote Shenzhen S.E., January 13, 2026

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Shenzhen S.E. Other stock markets 2026-01-14			5-day change	1st Jan Change
24.51 ^CNY	-1.17%		+1.03%	+3.59%

Dec. 05	Tranche Update on Tibet Cheezheng Tibetan Medicine Co., Ltd.'s Equity Buyback Plan announced on March 3, 2025.	CI
Dec. 04	Tibet Cheezheng Tibetan Medicine Co., Ltd.'s Equity Buyback announced on March 3, 2025, has closed with 5,821,355 shares, representing 1.06% for CNY 137.44 million.	CI

Capitalization	13.47B 1.93B 1.66B 1.54B 1.44B 2.68B 174B 2.89B 17.75B 6.98B 83.44B 7.25B 7.1B 306B	P/E ratio 2023	20.5x	P/E ratio 2024	19.5x
Enterprise value	12.17B 1.75B 1.5B 1.39B 1.3B 2.42B 158B 2.61B 16.04B 6.31B 75.4B 6.55B 6.41B 276B	EV / Sales 2023	5.42x	EV / Sales 2024	4.3x
Free-Float	10.76%	Yield 2023	2.13%	Yield 2024	1.78%

Dec. 05	Tranche Update on Tibet Cheezheng Tibetan Medicine Co., Ltd.'s Equity Buyback Plan announced on March 3, 2025.	CI
Dec. 04	Tibet Cheezheng Tibetan Medicine Co., Ltd.'s Equity Buyback announced on March 3, 2025, has closed with 5,821,355 shares, representing 1.06% for CNY 137.44 million.	CI
25-10-27	Tibet Cheezheng Tibetan Medicine Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
25-10-10	Tranche Update on Tibet Cheezheng Tibetan Medicine Co., Ltd.'s Equity Buyback Plan announced on March 3, 2025.	CI
25-09-15	Tibet Cheezheng Tibetan Medicine Co., Ltd. Announces Interim Cash Dividend on A Shares for the Year 2025, Payable on 22 September 2025	CI
25-08-25	Tibet Cheezheng Tibetan Medicine Co., Ltd. Proposes Dividend for the First Half of 2025	CI
25-07-28	Tibet Cheezheng Tibetan Medicine Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-07-02	Tranche Update on Tibet Cheezheng Tibetan Medicine Co., Ltd.'s Equity Buyback Plan announced on March 3, 2025.	CI
25-05-29	Tibet Cheezheng Tibetan Medicine Gets Regulatory Nod for Pediatric Drug Trials	MT
25-05-19	Cheezheng TTM Approves Cash Dividend Distribution for 2024	CI
25-04-25	Tibet Cheezheng Tibetan Medicine Co., Ltd. Proposes Final Cash Dividend for the Year 2024	CI
25-04-24	Tibet Cheezheng Tibetan Medicine Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-04-01	Tranche Update on Tibet Cheezheng Tibetan Medicine Co., Ltd.'s Equity Buyback Plan announced on March 3, 2025.	CI

1 day	-1.17%
1 week	+1.03%
Current month	+3.59%
1 month	-0.45%
3 months	-8.03%
6 months	+8.98%
Current year	+3.59%

Tibet Cheezheng Tibetan Medicine Co., Ltd. Stock

Equities

002287

CNE100000FM9

Pharmaceuticals

Valuation: Tibet Cheezheng Tibetan Medicine Co., Ltd.

Chart: Tibet Cheezheng Tibetan Medicine Co., Ltd.

Latest news: Tibet Cheezheng Tibetan Medicine Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Tibet Cheezheng Tibetan Medicine Co., Ltd.

Alternative Medicine

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	24.3	25.19
1 month	23.6	25.19
Current year	23.77	25.19
1 year	20.27	38.16
3 years	16.27	38.16
5 years	16.27	38.16
10 years	16.27	50.3

Manager	Title	Age	Since
Xiao Mei Yao DFI	Director of Finance/CFO	56	-
Kai Lie Liu PSD	President	62	2010-01-24
Yi Rui Wang AUD	Comptroller/Controller/Auditor	41	2019-09-25

Director	Title	Age	Since
Ju Fang Lei CHM	Chairman	73	2007-10-07
Kai Lie Liu BRD	Director/Board Member	62	2009-01-23
Ou Zhu Suo Lang BRD	Director/Board Member	61	2014-02-09

	2023	2024
Net sales	2.05B 293M 252M 234M 218M 407M 26.48B 439M 2.69B 1.06B 12.67B 1.1B 1.08B 46.41B	2.34B 335M 288M 268M 249M 465M 30.27B 501M 3.08B 1.21B 14.48B 1.26B 1.23B 53.06B
Net income	581M 83.35M 71.52M 66.59M 61.97M 116M 7.52B 125M 766M 301M 3.6B 313M 306M 13.19B	582M 83.51M 71.66M 66.72M 62.09M 116M 7.54B 125M 767M 302M 3.61B 313M 307M 13.21B
Net Debt	-831M -119M -102M -95.25M -88.64M -165M -10.76B -178M -1.1B -431M -5.15B -447M -438M -18.86B	-1.3B -186M -160M -149M -138M -258M -16.81B -279M -1.71B -673M -8.04B -699M -684M -29.47B

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-1.17%	+1.03%	+19.10%	+4.74%	2B
BEIJING TONGRENTANG CO., LTD	-2.34%	-1.86%	-16.40%	-31.23%	6.23B
DONG-E-E-JIAO CO.,LTD.	-1.13%	-2.45%	-20.95%	+14.37%	4.51B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	-1.82%	-2.04%	+51.47%	+44.67%	4.41B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	+0.11%	+0.51%	+11.11%	-39.82%	4.26B
HUBEI JUMPCAN PHARMACEUTICAL CO., LTD.	+0.12%	-0.57%	-7.67%	-8.16%	3.45B
TASLY PHARMACEUTICAL GROUP CO., LTD	-0.26%	+0.26%	+9.51%	+34.74%	3.28B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	+0.24%	+2.76%	+9.05%	-20.95%	2.53B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	-1.32%	-2.66%	-1.83%	+50.54%	1.69B
ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD	-0.06%	+3.05%	+12.44%	+61.26%	1.68B
Average	-0.76%	-0.14%	+6.58%	+11.02%	3.4B
Weighted average by Cap.	-0.93%	-0.52%	+4.74%	+3.76%